What should define a SARS-CoV-2 "breakthrough" infection?
J Clin Invest
.
2021 Jun 15;131(12):e151186.
doi: 10.1172/JCI151186.
Authors
John S Schieffelin
1
,
Elizabeth B Norton
2
,
Jay K Kolls
3
Affiliations
1
Tulane Department of Pediatrics.
2
Tulane Department of Microbiology and Immunology, and.
3
Center for Translational Research in Infection and Inflammation, Tulane School of Medicine, New Orleans, Louisiana, USA.
PMID:
33974565
PMCID:
PMC8203469
DOI:
10.1172/JCI151186
No abstract available
MeSH terms
COVID-19 / epidemiology
COVID-19 / immunology
COVID-19 / pathology
COVID-19 / prevention & control*
COVID-19 Vaccines / therapeutic use*
Humans
Immunity, Mucosal / drug effects*
SARS-CoV-2 / immunology*
Substances
COVID-19 Vaccines
Grants and funding
U54 CA260581/CA/NCI NIH HHS/United States
U54 GM104940/GM/NIGMS NIH HHS/United States